Bio-Rad Laboratories, Inc. (BIO) SEC Filings
Filing links are provided when reliable SEC filing data is available.
Recent Filings
| Form | Filing Date | Accepted | Document |
|---|---|---|---|
| SD | May 13, 2026 | May 13, 2026 | View filing |
| 4 | May 13, 2026 | May 13, 2026 | View filing |
| S-8 | Apr 30, 2026 | Apr 30, 2026 | View filing |
| 10-Q | Apr 30, 2026 | Apr 30, 2026 | View filing |
| 8-K | Apr 30, 2026 | Apr 30, 2026 | View filing |
| 4 | Apr 28, 2026 | Apr 28, 2026 | View filing |
| 4 | Apr 28, 2026 | Apr 28, 2026 | View filing |
| 8-K | Apr 24, 2026 | Apr 24, 2026 | View filing |
| 4 | Apr 23, 2026 | Apr 23, 2026 | View filing |
| 4 | Apr 23, 2026 | Apr 23, 2026 | View filing |
| 4 | Apr 23, 2026 | Apr 23, 2026 | View filing |
| 4 | Apr 23, 2026 | Apr 23, 2026 | View filing |
| SC 13G/A | Mar 26, 2026 | Mar 26, 2026 | View filing |
| ARS | Mar 25, 2026 | Mar 25, 2026 | View filing |
| DEF 14A | Mar 25, 2026 | Mar 25, 2026 | View filing |
| 8-K | Feb 19, 2026 | Feb 19, 2026 | View filing |
| 10-K | Feb 13, 2026 | Feb 12, 2026 | View filing |
| 8-K | Feb 12, 2026 | Feb 12, 2026 | View filing |
| 4 | Nov 10, 2025 | Nov 10, 2025 | View filing |
| SC 13D/A | Oct 30, 2025 | Oct 30, 2025 | View filing |
| SC 13D/A | Oct 30, 2025 | Oct 30, 2025 | View filing |
| 10-Q | Oct 29, 2025 | Oct 29, 2025 | View filing |
| 8-K | Oct 29, 2025 | Oct 29, 2025 | View filing |
| SC 13D/A | Oct 28, 2025 | Oct 28, 2025 | View filing |
| SC 13D/A | Oct 28, 2025 | Oct 28, 2025 | View filing |
| 4 | Oct 28, 2025 | Oct 28, 2025 | View filing |
| 4 | Oct 21, 2025 | Oct 21, 2025 | View filing |
| SC 13G/A | Oct 17, 2025 | Oct 17, 2025 | View filing |
| 8-K | Sep 30, 2025 | Sep 30, 2025 | View filing |
| 4 | Sep 9, 2025 | Sep 9, 2025 | View filing |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz